VRX Financial Facts

Income from continuing operations attributable to Valeant: 0.39
Service revenue: 4.4M
See Full Income Statement

Current deferred tax liabilities, net: 759K
Commitments and contingencies: 0
See Full Balance Sheet

Earnings History for Valeant Pharmaceuticals International (VRX)

  |   Expand Research on VRX
Next EPS Date 8/1/13 *Est. EPS Growth Rate +31.3% *Last Qtr.
Average EPS % Beat Rate +1,215.5% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +1.5%    
Date  Qtr EPS Cons. Surprise Revs Cons. Estimize EPS/Revs Gd. % Since Details
5/9/11 Q111 $0.02N/A N/A $565M$297.08M N/A / N/A +72% Details
11/4/10 Q310 -$1.27N/A N/A N/AN/A N/A / N/A N/A +204.3% Details
2/24/11 Q410 $0.51N/A N/A $514.6M$297.08M N/A / N/A +122.2% Details
5/3/12 Q112 $0.99$0.02 +$0.97N/AN/A $1.01 / $853.98M = +52.3% Details
8/4/11 Q211 $0.73N/A N/A $609M$297.08M N/A / N/A +64.6% Details
11/2/12 Q312 $1.15N/A N/A $884.1M$600.6M N/A / N/A = +51.5% Details
2/27/12 Q411 $0.94$0.84 +$0.10$688.4M$514.56M N/A / N/A = +79.4% Details
5/2/13 Q113 $1.30N/A N/A $1.07B$1.04B N/A / N/A +16.7% Details
Like VRX Earnings? Also take a look at ACT, MRX, OMPI, WCRX

VRX Earnings News